The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
Abstract
The recognition of the central role of interleukin (IL)-17A in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes. IL-17A also plays an important role in immunological protection against infections, especially those due to Candida spp., as evidenced by findings in patients with genetic defects in IL-17-related immune responses. To assess the potential of anti-IL-17 treatment to promote Candida infections, here we have systematically reviewed published clinical trials of patients with psoriasis or psoriatic arthritis. Candida infections were reported in 4·0% of patients treated with brodalumab, 1·7% with secukinumab and 3·3% with ixekizumab vs. 0·3%, 2·3% and 0·8% of those assigned to placebo, ustekinumab or etanercept, respectively. Although the incidence of Candida infection was found to be increased by only a small degree during anti-IL-17 therapy, patients undergoing such treatment should be monitored for fungal infection and treated as necessary. We propose adoption of the recently updated recommendations for the practical management of Candida infection in patients administered IL-17 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationMcInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationLiu, L., Okada, S., Kong, X.-F., Kreins, A. Y., Cypowyj, S., Abhyankar, A., Toubiana, J., Itan, Y., Audry, M., Nitschke, P., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110958 · Cited by 797
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis
van de Veerdonk, F. L., Plantinga, T. S., Hoischen, A., Smeekens, S. P., Joosten, L. A. B., Gilissen, C., Arts, P., Rosentul, D. C., Carmichael, A. J., Smits-van der Graaf, C. A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100102 · Cited by 666
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343
Blauvelt, A., Prinz, J. C., Gottlieb, A. B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13348 · Cited by 323
IL-17–Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans
Conti, H. R., & Gaffen, S. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500909 · Cited by 301
Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12751 · Cited by 280
Rich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12112 · Cited by 244
Mrowietz, U., Leonardi, C. L., Girolomoni, G., Toth, D., Morita, A., Balki, S. A., Szepietowski, J. C., Regnault, P., Thurston, H., & Papavassilis, C. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.04.011 · Cited by 208
Self-citationC-Type Lectin-Like Receptors of the Dectin-1 Cluster: Ligands and Signaling Pathways
Plato, A., Willment, J. A., & Brown, G. D. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.777065 · Cited by 200
Rich, P., Sigurgeirsson, B., Thaci, D. P., Ortonne, J.-P., Paul, C., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12070 · Cited by 189
Nakagawa, H., Niiro, H., & Ootaki, K. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.10.009 · Cited by 147
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
Huppler, A. R., Bishu, S., & Gaffen, S. L. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3893 · Cited by 147
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 140
Saeki, H., Nakagawa, H., Ishii, T., Morisaki, Y., Aoki, T., Berclaz, P., & Heffernan, M. P. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12773 · Cited by 130
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 117
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Papp, K. A., Leonardi, C. L., Menter, A., Thompson, E. H. Z., Milmont, C. E., Kricorian, G., Nirula, A., & Klekotka, P. A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.039 · Cited by 116
Gordon, K. B., Leonardi, C. L., Lebwohl, M., Blauvelt, A., Cameron, G. S., Braun, D. K., Erickson, J., & Heffernan, M. P. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.048 · Cited by 107
Ohtsuki, M., Morita, A., Abe, M., Takahashi, H., Seko, N., Karpov, A., Shima, T., Papavassilis, C., Nakagawa, H., & subgroup, T. E. S. J. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12668 · Cited by 92
Chen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Thaçi, D., Humeniuk, J. M., Frambach, Y., Bissonnette, R., Goodman, J. J., Shevade, S., Gong, Y., Papavassilis, C., & the STATURE study group (2015) · British Journal of Dermatology · doi:10.1111/bjd.13814 · Cited by 77
van der Heijde, D. M. F. M., Landewé, R., Mease, P. J., McInnes, I. B., Conaghan, P. G., Pricop, L., Ligozio, G., Richards, H. B., & Mpofu, S. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39685 · Cited by 73
A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
Armstrong, A. W., Bukhalo, M., & Blauvelt, A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0206-4 · Cited by 62
Ling, Y., & Puel, A. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(14)70016-x · Cited by 54
Gottlieb, A. B., Langley, R. G. B., Philipp, S., Sigurgeirsson, B., Blauvelt, A., Martin, R., Papavassilis, C., & Mpofu, S. (2015) · PubMed · Cited by 52
Picciani, B. L. S., Michalski-Santos, B., Carneiro, S. C. D. S., Sampaio, A. L., Avelleira, J. C. R., Azulay, D. R., Pinto, J. M. N., & Dias, E. P. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.11.033 · Cited by 52
Sarvtin, M. T., Shokohi, T., Hajheydari, Z., Charati, J. Y., & Hedayati, M. T. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12562 · Cited by 52
Whibley, N., Jaycox, J. R., Reid, D. M., Garg, A. V., Taylor, J. A., Clancy, C. J., Nguyen, M. H., Biswas, P. S., McGeachy, M. J., Brown, G. D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500870 · Cited by 51
Interleukin 17-A inhibition in the treatment of psoriasis
Yiu, Z. Z. N., & Griffiths, C. E. M. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1112739 · Cited by 40
Salt, E. G., Wiggins, A. T., Rayens, M. K., Huaman, M. A., Mannino, D. M., Schwieterman, P. A., Merkley, S. A., Jones, A. R., & Crofford, L. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39468 · Cited by 33
Oral Candida colonization and candidiasis in patients with psoriasis
Bedair, A., Darwazeh, A. M.-G., & AL‐ABOOSI, M. M. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.05.011 · Cited by 24
Cited by
IL-17 and IL-17-producing cells in protection versus pathology
Mills, K. H. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00746-9 · Cited by 1,000
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Kaymaz, K., & Beikler, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143394 · Cited by 534
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Metadata
- Authors
- Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-01
- Volume
- 177
- Issue
- 1
- Pages
- 47-62
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2517289120
- Cited by
- 270
- References
- 45
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.